These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8740082)

  • 21. Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis.
    Van Antwerpen P; Néve J; Moreau P; Boudjeltia KZ; Vanhaeverbeek M; Prévost M; Babar S; Legssyer I; Moguilevsky N; Ducobu J
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):350-1. PubMed ID: 17878766
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibitory effect of the new calcium antagonist AJ-2615 on progression of atherosclerosis in cholesterol-fed rabbits.
    Minato H; Ikeno A; Yamada T; Kato H; Zushi K; Kurokawa M; Masuda Y; Hosoki K; Karasawa T
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):663-9. PubMed ID: 7681914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effects of monatepil, a novel calcium antagonist with alpha 1-adrenergic-blocking activity, and nitrendipine on lipoprotein and carbohydrate metabolism in patients with hypertension.
    Sasaki J; Ogihara T; Yokoyama M; Kajiyama G; Mashiba H; Sunaga T; Nonaka K; Shichiri M; Tanaka N; Arakawa K
    Am J Hypertens; 1994 Oct; 7(10 Pt 2):161S-166S. PubMed ID: 7826567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-arrhythmic effects of a new calcium antagonist, monatepil, AJ-2615, in experimental arrhythmic models [corrected].
    Yamamoto T; Hosoki K; Karasawa T
    Clin Exp Pharmacol Physiol; 1993; 20(7-8):497-500. PubMed ID: 8403530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist.
    Bakshi VP; Geyer MA
    J Pharmacol Exp Ther; 1997 Nov; 283(2):666-74. PubMed ID: 9353384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.
    Thiéry V; Coudert G; Bizot-Espiard JG; Pfeiffer B; Renard P; Lindenbaum A; Guillaumet G
    J Med Chem; 2001 Nov; 44(23):3904-14. PubMed ID: 11689076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment.
    Moghadasian MH; Nguyen LB; Shefer S; Salen G; Batta AK; Frohlich JJ
    Metabolism; 2001 Jun; 50(6):708-14. PubMed ID: 11398149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
    Keledjian K; Kyprianou N
    J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDL-antioxidant pterocarpans from roots of Glycine max (L.) Merr.
    Lee JH; Lee BW; Kim JH; Jeong TS; Kim MJ; Lee WS; Park KH
    J Agric Food Chem; 2006 Mar; 54(6):2057-63. PubMed ID: 16536575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
    Sundell CL; Somers PK; Meng CQ; Hoong LK; Suen KL; Hill RR; Landers LK; Chapman A; Butteiger D; Jones M; Edwards D; Daugherty A; Wasserman MA; Alexander RW; Medford RM; Saxena U
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1116-23. PubMed ID: 12626663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of lipoprotein bound copper ions in lipid peroxidation of low and high density lipoproteins].
    Vakhrusheva TV; Dremina ES; Sharov VS; Azizova OA
    Biofizika; 1997; 42(3):662-70. PubMed ID: 9296625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftriaxone induced lipid peroxidation and its inhibition with various antioxidants: Part II. Evaluation of glutathione and probucol as antioxidants.
    Roy K; Saha A; De K; Sengupta C
    Acta Pol Pharm; 2000; 57(5):385-90. PubMed ID: 11126031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacophore-based design, synthesis, biological evaluation, and 3D-QSAR studies of aryl-piperazines as alpha(1)-adrenoceptor antagonists.
    Li MY; Fang H; Xia L
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3216-9. PubMed ID: 15935663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals.
    Napoli C; Chiariello M; Palumbo G; Ambrosio G
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):417-24. PubMed ID: 8924055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New therapeutic trends in calcium antagonism. Are they meaningful?
    Nayler WG
    Am J Hypertens; 1994 Oct; 7(10 Pt 2):126S-130S. PubMed ID: 7826562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AJ-2615, a long-acting Ca2+ channel antagonist with a novel structure.
    Liu GJ; Takeuchi H
    Eur J Pharmacol; 1993 Jan; 231(1):91-5. PubMed ID: 8444284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL.
    Kinoshita M; Shimazu N; Fujita M; Fujimaki Y; Kojima K; Mikuni Y; Horie E; Teramoto T
    Am J Hypertens; 2001 Mar; 14(3):267-70. PubMed ID: 11281239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous determination of a novel calcium entry blocker, monatepil maleate, and its metabolites in rat plasma by means of solid-phase extraction and reversed-phase liquid chromatography with electrochemical detection.
    Kurono M; Suzuki K; Yoshida K; Naruto S
    J Chromatogr B Biomed Sci Appl; 1997 Feb; 689(2):427-32. PubMed ID: 9080333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive quantitative evaluation of early atherosclerosis and the effect of monatepil, a new antihypertensive agent. An interim report.
    Tsushima M; Koh H; Suzuki M; Kyotani S; Waki M; Nishioeda Y; Harano Y; Omae T
    Am J Hypertens; 1994 Oct; 7(10 Pt 2):154S-160S. PubMed ID: 7826566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological correction of lipid peroxidation during hypoxia and possibility to enhance human resistance to high altitude by using preparations of the metabolic type of action].
    Nagornev SN; Sytnik SI; Bobrovnitskiĭ IP; Cherniakov IN; Shishov AA
    Vestn Ross Akad Med Nauk; 1996; (7):53-60. PubMed ID: 8963183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.